AstraZeneca’s Recentin Will Move Into Phase III For Colorectal Cancer, But Not NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will study VEGF inhibitor plus chemotherapy versus Genentech’s Avastin in first-line colorectal cancer.